Back

PERFORM score: a predictive prognostic tool for anticipating the requirement for fibrinolysis in pulmonary embolism

13 May 2024 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 1 Pulmonary Embolism (PE) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mariana Duarte Almeida

Hospital Center Tondela Viseu, Viseu (Portugal)

7 More presentations in this session

Presentation thumbnail
Relationship between dynamics of cardiac sympathetic innervation, assessed with 123I-MIBG SPECT, exercise capacity and left ventricular reverse remodelling in dilated cardiomyopathy
Doctor E. Dziewiecka (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
The genetic architecture of dilated cardiomyopathy in Hungary: analysis of 135 patients with a panel of 98 genes
Doctor H. Takacs (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Prevalence and predictors of normotensive cardiogenic shock in intermediate-high risk pulmonary embolism.
Doctor B. Lacerda Teixeira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Hyponatremia as a predictor of short-term mortality in patients with pulmonary embolism
Doctor J. Gouveia Fiuza (Viseu, PT)
Abstract Slides Video
Presentation thumbnail
Short and long-term mortality in patients with acute pulmonary embolism: focus on cancer-related disease.
Doctor I. Santos (Ponta Delgada, PT) Doctor F. Duarte (Ponta Delgada, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 1

The Event

Event poster

Heart Failure 2024

13 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Risk assessment in patients with intermediate to high-risk pulmonary embolism: can the validated scores help predict the necessity of reperfusion therapy?
thumbnail
Congress Session
Pulmonary embolism: assessment and outcomes
thumbnail
Congress Presentation
TELOS-plus identifies normotensive patients with pulmonary embolism at high risk (>10%) of 30-day mortality

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources